Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCARDIOVASCULAR

The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins

Cort S. Madsen, Evan Janovitz, Rongan Zhang, Van Nguyen-Tran, Carol S. Ryan, Xiaohong Yin, Hossain Monshizadegan, Ming Chang, Celia D'Arienzo, Susan Scheer, Robert Setters, Debra Search, Xing Chen, Shaobin Zhuang, Lori Kunselman, Andrew Peters, Thomas Harrity, Atsu Apedo, Christine Huang, Carolyn A. Cuff, Mark C. Kowala, Michael A. Blanar, Chong-qing Sun, Jeffrey A. Robl and Philip D. Stein
Journal of Pharmacology and Experimental Therapeutics February 2008, 324 (2) 576-586; DOI: https://doi.org/10.1124/jpet.107.131615
Cort S. Madsen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evan Janovitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rongan Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Van Nguyen-Tran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol S. Ryan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohong Yin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hossain Monshizadegan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia D'Arienzo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Scheer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Setters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Debra Search
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xing Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaobin Zhuang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lori Kunselman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Peters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Harrity
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsu Apedo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Huang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn A. Cuff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark C. Kowala
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Blanar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chong-qing Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey A. Robl
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip D. Stein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Statins, because of their excellent efficacy and manageable safety profile, represent a key component in the current armamentarium for the treatment of hypercholesterolemia. Nonetheless, myopathy remains a safety concern for this important drug class. Cerivastatin was withdrawn from the market for myotoxicity safety concerns. BMS-423526 [{(3R,5S)-7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-heptenoic acid} sodium salt], similar to cerivastatin in potency and lipophilicity, was terminated in early clinical development due to an unacceptable myotoxicity profile. In this report, we describe the guinea pig as a model of statin-induced cholesterol lowering and myotoxicity and show that this model can distinguish statins with unacceptable myotoxicity profiles from statins with acceptable safety profiles. In our guinea pig model, both cerivastatin and BMS-423526 induced myotoxicity at doses near the ED50 for total cholesterol (TC) lowering in plasma. In contrast, wide differences between myotoxic and TC-lowering doses were established for the currently marketed, more hydrophilic statins, pravastatin, rosuvastatin, and atorvastatin. This in vivo model compared favorably to an in vitro model, which used statin inhibition of cholesterol synthesis in rat hepatocytes and L6 myoblasts as surrogates of potential efficacy and toxicity, respectively. Our conclusion is that the guinea pig is a useful preclinical in vivo model for demonstrating whether a statin is likely to have an acceptable therapeutic safety margin.

Footnotes

  • ↵1 An ascending multiple-dose clinical study was conducted in healthy subjects to examine the safety, pharmacokinetics, and pharmacodynamics of BMS-423526 following once daily administration for 14 days. The mean percentage decrease in plasma levels of LDLc relative to baseline was 18 (0.5 mg), 34 (1 mg), 38 (2.5 mg), 54 (5 mg), 52 (10 mg), 57 (20 mg), and 56% (40 mg). Elevated plasma CK (>10 times the upper limit of normal) was noted in one subject (of six) at the 20-mg dose and also in four of six subjects treated with 40 mg, three of whom manifested reversible rhabdomyolysis.

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

  • doi:10.1124/jpet.107.131615.

  • ABBREVIATIONS: HMGR, 3-hydroxy-3-methylglutaryl-CoA reductase; atorvastatin, {(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid} calcium salt; rosuvastatin, {(3R,5R)-7-[4-(4-fluorophenyl)-2-(methylmethylsulfonyl-amino)-6-propan-2-yl-pyrimidin-5-yl]-3,5-dihydroxy-heptanoic acid} calcium salt; BMS-423526, {(3R,5S)-7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-heptenoic acid} sodium salt; cerivastatin, {(3R,5S)-7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-dipropan-2-yl-pyridin-3-yl]-3,5-dihydroxy-heptanoic acid} sodium salt; pravastatin, {(3R,5R)-7-[(1S,2R,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid} sodium salt; CK, creatine kinase; TC, total cholesterol; LC/MS/MS, liquid chromatography tandem mass spectroscopy; HPLC, high-performance liquid chromatography; LDLc, low-density lipoprotein cholesterol; KRB, Krebs-Ringer buffer.

    • Received September 13, 2007.
    • Accepted November 5, 2007.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 387 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 387, Issue 1
1 Oct 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCARDIOVASCULAR

The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins

Cort S. Madsen, Evan Janovitz, Rongan Zhang, Van Nguyen-Tran, Carol S. Ryan, Xiaohong Yin, Hossain Monshizadegan, Ming Chang, Celia D'Arienzo, Susan Scheer, Robert Setters, Debra Search, Xing Chen, Shaobin Zhuang, Lori Kunselman, Andrew Peters, Thomas Harrity, Atsu Apedo, Christine Huang, Carolyn A. Cuff, Mark C. Kowala, Michael A. Blanar, Chong-qing Sun, Jeffrey A. Robl and Philip D. Stein
Journal of Pharmacology and Experimental Therapeutics February 1, 2008, 324 (2) 576-586; DOI: https://doi.org/10.1124/jpet.107.131615

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleCARDIOVASCULAR

The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins

Cort S. Madsen, Evan Janovitz, Rongan Zhang, Van Nguyen-Tran, Carol S. Ryan, Xiaohong Yin, Hossain Monshizadegan, Ming Chang, Celia D'Arienzo, Susan Scheer, Robert Setters, Debra Search, Xing Chen, Shaobin Zhuang, Lori Kunselman, Andrew Peters, Thomas Harrity, Atsu Apedo, Christine Huang, Carolyn A. Cuff, Mark C. Kowala, Michael A. Blanar, Chong-qing Sun, Jeffrey A. Robl and Philip D. Stein
Journal of Pharmacology and Experimental Therapeutics February 1, 2008, 324 (2) 576-586; DOI: https://doi.org/10.1124/jpet.107.131615
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Compression no-reflow in intestinal ischemia-reperfusion
  • Rapid Characterization of Cantú Syndrome Mutations
  • Vericiguat: Nonclinical Cardiovascular Assessment
Show more Cardiovascular

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics